Respiri Limited ( (AU:RSH) ) has issued an announcement.
Respiri Limited has announced the issuance of 72,847,867 fully paid ordinary shares, in compliance with the Corporations Act 2001. This strategic move is part of the company’s ongoing efforts to strengthen its market position and expand its innovative healthcare solutions, including the wheezo® device, which enhances chronic disease management through advanced technology and strategic partnerships.
More about Respiri Limited
Respiri Limited is an innovative company in the medical devices and MedTech industry, focusing on transforming healthcare delivery in the US. They specialize in remote healthcare solutions, offering cutting-edge technologies and clinical expertise to manage chronic conditions. Their flagship product, wheezo®, is a revolutionary FDA-approved device for respiratory disorder management, integrating seamlessly into healthcare systems to enhance efficiency and reduce costs.
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $37.78M
Find detailed analytics on RSH stock on TipRanks’ Stock Analysis page.